COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Scorching week forecast for various parts of country
- Young filmmakers' project paints multidimensional portrait of China
- Rare 1938 Guangzhou bombing photos to debut in August
- Power station solves renewable energy intermittency
- China appoints senior official for Hong Kong, Macao affairs
- World-first study analyzes minerals on far side of moon
